Deutsche Bank Remains a Buy on Novartis (NVS) With a CHF115 PT

Novartis AG (NYSE:NVS) is one of the 10 Undervalued European Stocks to Invest in Now. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NYSE:NVS) on June 9, setting a price target of CHF115.00.

The company announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial on June 2, reporting that the trial met its primary endpoint. It demonstrated a clinically meaningful and statistically significant benefit for Pluvicto™ plus hormone therapy compared to hormone therapy alone, reflecting a positive trend in overall survival (OS).

Pluvicto™ already holds approval for metastatic castration-resistant prostate cancer (mCRPC) and has now begun to show potential in patients in an earlier disease setting. Novartis AG (NYSE:NVS) plans to submit for regulatory review in the second half of the year, depending upon FDA feedback.

Novartis AG (NYSE:NVS) holds the fourth spot on our list of the top undervalued European stocks to buy now. Headquartered in Basel, Switzerland, the company develops, markets, and manufactures a range of healthcare products. Its operations span the Innovative Medicines, Sandoz, and Corporate segments.

While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.